Skip to Main Content
Oncology CRO Services
Full Service CRO
Clinical Analytics
Site Network
Consulting
Development Phase
Early Phase Research Catalyst Oncology, an oncology clinical research organization, works with innovative biotechs on a range of early phase study designs and therapies.
Late Phase Research Catalyst Oncology helps move oncology therapies through the complex and dynamic clinical trial environment with workable solutions, best-in-class technologies, and a data-centric approach.
Case Study
Immuno-Oncology
Helping to bring immunotherapies to cancer patients in need
Read more
Insights
Contact Us
Oncology CRO Services
Full Service CRO
Clinical Analytics
Site Network
Consulting
Development Phase
Early Phase ResearchCatalyst Oncology, an oncology clinical research organization, works with innovative biotechs on a range of early phase study designs and therapies.
Late Phase ResearchCatalyst Oncology helps move oncology therapies through the complex and dynamic clinical trial environment with workable solutions, best-in-class technologies, and a data-centric approach.
Case Study
Immuno-Oncology
Helping to bring immunotherapies to cancer patients in need
Read more
Insights
Contact Us

Advancing Lung Cancer Trials with Precision

June 26, 2025
Lung cancer is the second most diagnosed cancer and the leading cause of cancer-related deaths globally.

In 2022, lung cancer accounted for 2.5 million new cases and over 1.8 million deaths—18% of all cancer mortalities. Ongoing research is driving new treatments that improve quality of life and offering renewed hope against this aggressive disease.

 

Lung cancer trial expertise

Catalyst Oncology brings deep expertise in lung cancer trials, from first-in-human (FIH) through to global 200+ patient studies. These studies often require global reach, complex logistics, country-specific regulatory hurdles, and advanced data review to manage safety and mitigate risks. They can also experience recruitment challenges due to strict eligibility criteria, evolving standards of care, and biomarker-selective populations.

Catalyst Oncology overcomes lung cancer trial challenges with access to top-performing sites, regulatory insights, and operational excellence.

Icon of cancer cell
Robust pipeline of lung cancer trials
  • Global footprint
    • North America, Europe, and APAC
  • Study experience
    • 10+ active early and late phase studies with 2900+ patients
    • NSCLC and SCLC
  • Site experience
    • 120+ investigative sites in 8 countries
  • Innovative next-gen therapies
    • ADCs
    • Cell therapies
We understand lung cancer trials
  • Enrollment challenges
    • Diagnosis at advanced stage
    • Disease stigma, e.g., smoking
    • Strict I/E criteria
  • Treatment difficult due to disease heterogeneity and various subtypes and genetic mutations
  • Targeted therapy treatment varies
    • Biomarker specific
    • Specific genetic mutation

Info Sheet

Recently Published

View All
Highlights text for 2025 ASCO annual meeting Blog Highlights of ASCO 2025 Translating research into real-world results for cancer patients I joined over 45,000 oncology professionals at McCormick Read Now
Highlights from CTO West Coast 2025 Blog Highlights from Clinical Trials in Oncology West Coast 2025 Exploring innovation, patient-centricity, and operational excellence in trials I was thrilled to attend the annual Read Now
Graphic with medical professional and stethoscope and artificial intelligence word cloud. Blog Artificial Intelligence in Oncology Clinical Trials Transforming drug development Artificial intelligence (AI) is revolutionizing nearly every aspect of our work and Read Now
View All
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.